Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
NPS Pharmaceuticals, Inc.
Type
Public limited company
Traded as LSE: SHP, NASDAQ: SHPG
Industry Pharmaceuticals
Predecessor Shire Pharmaceuticals Group Plc
Founded 1986
Headquarters Registered Office: St Helier, Jersey
Corporate HQ: Dublin, Ireland
UK Operations: Basingstoke, England
Key people
Matthew Emmens (Chairman)
Flemming Ørnskov, MD (CEO)
Revenue $6,022.1 million (2014)
Operating income
$2,593.0 million (2014)
Net income
$2,088.5 million (2014)
Number of employees
5,300 (2014)
Website www.shire.com

Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft.

Foresight Biotherapeutics
(Acq 2015 by Shire)

Meritage Pharma
(Acq 2015 by Shire)

NPS Pharmaceuticals
(Acq 2015 by Shire)

Lumena
(Acq 2014 by Shire)

Fibrotech
(Acq 2014 by Shire)

ViroPharma
(Acq 2013 by Shire)

Lev Pharmaceuticals

SARcode Bioscience Inc
(Acq 2013 by Shire)

Premacure AB
(Acq 2013 by Shire)

Lotus Tissue Repair, Inc
(Acq 2013 by Shire)

FerroKin BioSciences
(Acq 2012 by Shire)

Advanced BioHealing
(Acq 2011 by Shire)

Movetis
(Acq 2012 by Shire)

Jerini
(Acq 2008 by Shire)

New River Pharmaceuticals Inc
(Acq 2007 by Shire)

Transkaryotic Therapeutics
(Acq 2005 by Shire)

Biochem Canada
(Acq 2001 by Shire)

Richwood Pharmaceutical Company
(Acq 1997 by Shire)

Investment goal date:
Dividends reinvested
NPS Pharmaceuticals, Inc. NPSP report Q3 2014
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2015
2015-05-07
--
--
Q4 2014
2015-02-18
--
--
Q3 2014
2014-11-10
-0.0200
-0.0200
Q2 2014
2014-08-06
0.0200
0.0200
Q1 2014
2014-05-08
-0.0600
-0.0600
Q4 2013
2014-02-18
0.0700
0.0700
Q3 2013
2013-11-06
-0.0100
-0.0100
Q2 2013
2013-08-08
-0.1300
-0.1300
Q1 2013
2013-05-09
-0.0900
-0.0900
Q4 2012
2013-02-21
-0.1400
-0.1400
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
Melrose Glenn R
0.0300% (26971)
NPSP /
% ()